The Rabies Diagnostics Market is vital to the healthcare industry, driven by rising rabies infections worldwide. This market focuses on developing and selling diagnostic tools and tests to detect and confirm rabies in animals and humans.
One of the most significant market determinants is the increased incidence of rabies worldwide, particularly in countries with poor healthcare infrastructure and limited preventive therapies. Rabies diagnostics that are fast and efficient are in demand, which has grown the market.
Diagnostic technologies are evolving, as the industry observes. PCR and RT-PCR are becoming more widespread because they can detect rabies with high sensitivity and specificity. Industrial growth depends on these technical advancements.
Government policies and legislation impact the Rabies Diagnostics Market. Due to strict livestock vaccination and control laws and awareness initiatives, diagnostic solutions are used. This industry receives government support for research and development.
Improved veterinarian preventative care impacts the business. boosted pet ownership and awareness of zoonotic illnesses like rabies have boosted need for effective and simple veterinary diagnostic technologies.
Globalization of the veterinary diagnostics industry also drives market expansion. Partnerships between global diagnostic companies and local players make rabies diagnostic products more accessible in many regions.
Research & development funding is crucial to Rabies Diagnostics Market innovation. Businesses are investing in novel diagnostic technologies with higher sensitivity and specificity and fast turnaround times to meet medical professionals' shifting needs.
Public awareness initiatives by government and non-government organizations are key market drivers. These initiatives warn the public against rabies and emphasize the need of accurate and timely diagnostics for disease treatment.
Diagnostic solutions that are cost-effective and efficient are in demand. As healthcare organizations save expenses, accurate, affordable diagnostic options are becoming increasingly popular. This is particularly significant in communities with little healthcare funds.
Partnerships between research institutes, healthcare groups, and diagnostic enterprises boost industrial vitality. These agreements accelerate the development and commercialization of breakthrough rabies diagnostics by pooling knowledge, resources, and technology.
The frequency of rabies varies by region, affecting diagnostic needs. Rabies-endemic areas have a strong diagnostic market. Rabies Diagnostics Market companies must understand and manage geographical differences.
Market challenges in low-resource regions include infrastructural limits that make contemporary diagnostic equipment harder to get. Diagnostic services must be affordable and portable to penetrate such markets.
The Rabies Diagnostics Market Size was valued at USD 2.11 Billion in 2023. The global rabies diagnostics industry is projected to grow from USD 2.26 Billion in 2024 to USD 3.56 Billion by 2032, exhibiting a CAGR of 5.21% during the forecast period (2024 - 2032).
Rabies spread through an animal bite or saliva with symptoms like fever, muscle spasms, excess salivation, headache, and mental instability.
The common rabies diagnostic methods include the Fluorescent Antibody Test (FAT), Direct Fluorescent Antibody (DFA) test, immunohistochemical tests, and amplification methods. The key market driving factor is the rise in awareness and concern for animal-related diseases. The growing awareness programs initiated by the government to fight against rabies and the growing necessity of immunization for humans and animals are enhancing the market. The surveillance strategies and development of rabies diagnostics kits contribute to the market's growth.
Major initiatives such as dog vaccinations, post-exposure prophylaxis (PEP) adoption, and the government's involvement in the laws regarding the diagnosis of rabies virus are aiding the market's growth. The rabies diagnostics market is accelerated by the rise in the adoption of advanced diagnostic solutions for rabies, the collaborations between research institutes and healthcare companies, novel rabies detection assays and kit development, and the initiatives organizations undertake to control the spread of rabies are factors propelling the market. The adoption of cutting-edge technologies for rabies diagnostic solutions is influencing more demand. On the other hand, the investments to support ongoing research activities and the invention of rabies diagnosis kits will increase the market's growth opportunities. The key player’s developments will boost the market.
The global rabies diagnostics market has been segmented on the basis of method, technology, end-user, and region.
On the basis of method, the market has been classified as a fluorescent antibody test (FAT), immunohistochemical test, amplification methods, histologic examination, and serology tests.
Also, by technology, the market has been segmented into ELISA/immunohistochemistry, chromatography techniques, PCR, and others.
Based on end-user, the market has been divided into hospitals, diagnostic centers, cancer palliative care clinics, and others. By end-user hospitals are likely to register the highest CAGR owing to the rising prevalence of rabies in emerging countries during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rabies diagnostics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rabies diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Asia-Pacific is likely to dominate the rabies diagnostics market during the forecast period owing to the improving healthcare infrastructure, rising investments in healthcare and expansions by market players in the region. Also, countries such as India and China are considering the fastest growing region due to a government focused toward adopting new technology and the best treatment option from a developed country. According to the World Health Organization, in 2010, the healthcare expenditure of India was 3.27% of GDP, whereas, in 2015 it has 3.89% of total GDP.
The Americas are likely to be the second-largest market in the global rabies diagnostics market owing to the rising strategic alliance by major players, increasing awareness about rabies, the involvement of non-profit organization to control rabies, and well-established healthcare infrastructure. According to the American Pet Products Association's 2017-2018 National Pet Owners Survey, Number of animals in the American region is increasing, and there were around 60.2 million dogs, and 47.1pet cats were present in the Americas.
The European market is expected to hold a significant share in the rabies diagnostics market. The market growth in this region can be attributed to the government funding, well-established healthcare sector, and support of the healthcare sector coupled with increasing research and development.
The market in the Middle East & Africa is expected to account for the smallest share of the global rabies diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Rabies Diagnostics Market Key Players
Some of the key players in the global Rabies Diagnostics Market are
Recent Development
In April 2022
Cadila Pharmaceuticals announced that it had developed the world's first novel three-dose vaccine against rabies. The three-dose vaccine, named 'ThRabis,' is a recombinant nano-particle-based G protein vaccine prepared using Virus-like Particle technology.
The company added that the three-dose schedule is spread over one week.
The new vaccine will prove to be a game-changer because all the other rabies vaccines require five injections over 28 days to eliminate the threatCadila, Pharmaceuticals said at the launch ceremony of the new vaccine.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)